Mallinckrodt (Mallinckrodt) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Mallinckrodt 5-Year EBITDA Growth Rate?

Mallinckrodt's EBITDA per Share for the three months ended in Sep. 2023 was $-17.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mallinckrodt was 51.90% per year. The lowest was -44.20% per year. And the median was 11.50% per year.

Competitive Comparison of Mallinckrodt's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mallinckrodt's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's 5-Year EBITDA Growth Rate falls into.

Mallinckrodt 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Mallinckrodt (OTCPK:MNKKQ) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Mallinckrodt 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MNKKQ) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Myers Woodrow A Jr	director	1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Fyi S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Ffi Iii S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Daniel Arthur Celentano	director	2831 S. BAYSHORE DRIVE, UNIT 2103, MIAMI FL 33133
Riad Hussein El-dada	director	910 TALAMORE DRIVE, AMBLER PA 19002
Bracebridge Capital, Llc	10 percent owner	888 BOYLSTON STREET, SUITE 1500, BOSTON MA 02199
Kassie Harrold	officer: Chief Compliance Officer	C/O MALLINCKRODT PHARMACEUTICALS, 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Neal P Goldman	director	10700 PARKRIDGE BLVD., RESTON VA 20191
Steven J. Romano	officer: EVP & Chief Sci. Ofcr	675 MCDONNELL BLVD., HAZELWOOD MO 63042
David Y Norton	director	8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Carlos V Paya	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James R Sulat	director